All News
Hypertension Increased in Psoriasis Treated with NSAIDs, Cyclosporine or Steroids
Psoriasis and psoriatic arthritis patient have significantly higher rates of comorbidity, including hypertension (HTN). This population-based, nested case–control study analyzed an inception psoriasis cohort from Taiwan's National Health Insurance Research Database between 2000–2010.
Read Article
Biology of Bone Remodeling in Psoriatic Disease
Paine and Ritchlin have reviewed the evidence that new bone formation is centered around enthesial sites and that such findings are evident in psoriatic arthritis as well as psoriasis patients without arthritis.
Read Article
Biosimilars and the FDA
Biosimilars are in the news and will be prominently on parade at next week's ACR meeting in San Francisco. Biosimilars are similar to, but not the same as, innovator biologics.
Read Article
Repeat Skin Cancer Risk with Methotrexate and Biologics
Using Medicare claims data, a retrospective cohort study analyzed the risk of a second non-melanomatous skin cancer (NMSC) in 9460 individuals (6841 with RA and 2788 with IBD).
Read Article
High Level Skin Responses Seen with Inhibitor of IL-23p19 in Psoriasis
Rheumatology News reports the results of a novel trial presented at the European Academy of Dermatology and Venereology meeting in Copenhagen.
Read Article
Vertebral Fractures in 10% of Spondyloarthritis Patients
Vertebral fractures are not uncommon in patients with ankylosing spondylitis and spondyloarthritis.
Read Article
Weight Loss Improves Skin Outcomes in Psoriasis
A recent presentation at the European Academy of Dermatology and Venereology (EADV) meeting in Copenhagen showed the long-term outcomes of weight loss in psoriasis.
Read Article
FDA Holds Off on Xeljanz Approval for Psoriasis
The FDA has denied Pfizer's application seeking an indication for Xeljanz in patients with moderate to severe chronic plaque psoriasis.
Read Article
Brodalumab vs. Ustekinumab: Head-to-Head Studies of Psoriasis
AMAGINE-2 and AMAGINE-3 are in two phase 3 studies that compare multiple doses of brodalumab (anti-IL-17) and ustekinumab (anti-12/23) in adults with moderate-to-severe psoriasis.
Read Article
Ustekinumab Effective in Adolescents with Psoriasis
Biologic and new drug development seldom targets children and adolescents. This study evaluated the efficacy and safety of ustekinumab in adolescents age 12 to 17 years with moderate-to-severe psoriasis,
Read Article
Secukinumab Wins in Psoriatic Arthritis
Mease and colleagues have published their results of a phase 3 trial of secukinumab (anti-IL-17A Mab) in 606 patients with psoriatic arthritis (PsA).
Read Article
TICOPA Study: Tight Control in Psoriatic Arthritis
Tight control in rheumatoid arthritis was introduced with the TICORA trial and validated in numerous treat-to-target studies since. Now the benefits of tight control in psoriatic arthritis (PsA) have been reported.
Read Article
ACR/SPARTAN 2015 Recommendations for Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis
The ACR and SPARTAN (Spondyloarthritis Research and Treatment Network) has worked together to study 57 specific treatment questions regarding AS and SpA. The following guidelines have recently been published after conducting systematic literature reviews.
Read Article
Dr. Woodcock Gives Senate FDA Update on Biosimilars
Biologics have been a great advance in therapeutics, but at great cost. Although biologics account for less than 1% of all prescriptions in the USA, they account for 28% percent of the cost of prescribed medications.
Read Article
Biosimilar SB4 Performs Equally to Etanercept
Biosimilars are rapidly growing. Many of these will have their first introduction to countries outside of the USA. There is concern whether biosimilars will provide identical pharmacodynamics, biological function, efficacy and toxicity to reference products, both in the short and long term.
Read Article
Future 2 Trial Shows Secukinumab Efficacy in Psoriatic Arthritis
Secukinumab (Cosentyx) is an anti-IL-17 monoclonal antibody currently approved for use in moderate to severe psoriasis. It has also been studied in psoriatic arthritis (PsA) and shown to be safe and effective.
Read Article
Is Early Use of TNFi in Spondyloarthritis Overkill or a Necessity?
Axial SpA (axSpA) is a chronic inflammatory disease that includes AS and non-radiographic axSpA (nr-axSpA).
Read Article
Monitoring of Novel Therapies in Rheumatology
The rheumatology therapeutic landscape has changed almost yearly in the last 15 years, with the introduction of at least 16 biologic or novel agents for the treatment of rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS), spondyloarthritis (SpA), juvenile arthritis,
Read Article
Higher Death Rates in Ankylosing Spondylitis
A nationwide study of 8600 ankylosing spondylitis (AS) patients from Sweden, compared survival to 40,460 controls between 2006-2012.
Read Article
